drugset
Drugs / GMEB-SASS
last change Jan 2026 re-read 3 minutes ago

GMEB-SASS

also known as Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute

Cell therapy

Developed for
recessive dystrophic epidermolysis bullosa
Investigated by
CHU de Quebec-Universite Laval

Trials 1

today NCT07193134 · Ph 1/2
202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07193134 Jan 2026 → Dec 2030 expected recessive dystrophic epidermolysis bullosa CHU de Quebec-Universite Laval Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GMEB-SASS ClinicalTrials.gov intervention name — accepted as the source's own label NCT07193134 ↗
Known as Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute “Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)” NCT07193134 ↗
Action Restore “will restore a functional dermo-epidermal junction” NCT07193134 ↗
Modality Cell therapy “The GMEB-SASS graft contains two types of living skin cells: keratinocytes and fibroblasts.” NCT07193134 ↗